A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Non-small Cell Lung Cancer|Breast Cancer|Gastric Cancer|Renal Cell Carcinoma|Ovarian Cancer|Primary Peritoneal Carcinoma|Fallopian Tube Cancer|Cholangiocarcinoma|Bladder Urothelial Carcinoma|MSI-H Colorectal Cancer|Esophageal Cancer|Hepatic Cancer|Head and Neck Cancer|Other Solid Tumors
Interventions: DRUG: CDX-527
Sponsor: Celldex Therapeutics